Hodgkin’s lymphoma is one of the most treatable cancers, with five-year survival rates ranging from about 83% for stage IV disease to over 95% for stage II. Treatment typically involves chemotherapy, often combined with radiation, and the specific plan depends on the stage of your disease, the size of affected lymph nodes, and your overall health. Newer targeted therapies and immunotherapies have expanded options significantly, especially for advanced or relapsed cases.
Chemotherapy as the Foundation
Nearly every Hodgkin’s lymphoma treatment plan starts with chemotherapy. The most common regimen for early-stage disease is a combination of four drugs known as ABVD, given in cycles over several months. For advanced-stage disease (stage III or IV), there are two main paths. One adds a targeted drug called brentuximab vedotin to a modified version of the standard chemotherapy, a combination that became a frontline standard after a large trial showed improved overall survival. The other option is an intensified seven-drug regimen called escalated BEACOPP, which produces higher complete response rates after just two cycles (78% vs. 67% for ABVD) but comes with more severe side effects.
The choice between these approaches depends partly on risk scoring. Patients with higher-risk features, such as widespread disease or significant symptoms, may benefit more from the intensified regimen. Most treatment centers now use PET scans after the first two cycles to see how well the cancer is responding, which can guide whether to continue the current plan or adjust it.
When Radiation Is Added
Radiation therapy is most commonly used alongside chemotherapy for early-stage Hodgkin’s lymphoma, where the disease is confined to one or two regions. Modern radiation for Hodgkin’s has gotten much more precise. Older approaches treated broad areas of the body, but current techniques focus tightly on the specific sites where disease was present at diagnosis, sparing surrounding healthy tissue. This approach, called involved-site radiation therapy, targets only the lymph nodes and tissues that were originally affected, relying on chemotherapy to handle any microscopic disease nearby.
For advanced-stage disease, radiation is less commonly part of the initial plan but may be used to treat bulky masses that don’t fully respond to chemotherapy.
Targeted Therapy and Immunotherapy
Two newer classes of drugs have changed the treatment landscape for Hodgkin’s lymphoma. Brentuximab vedotin is a targeted therapy that works by attaching to a protein called CD30 on the surface of Hodgkin’s lymphoma cells, then delivering a cell-killing payload directly inside them. This precision approach means less damage to healthy cells compared to traditional chemotherapy. Based on the ECHELON-1 trial, which showed an overall survival benefit at long-term follow-up, brentuximab combined with chemotherapy is now a standard frontline option for advanced-stage disease, a position reinforced in the most recent NCCN clinical guidelines.
Immunotherapy drugs called PD-1 inhibitors, such as nivolumab, work differently. They block a signal that cancer cells use to hide from the immune system, essentially removing the brakes on your body’s own immune response. PD-1 inhibitors have shown strong activity in Hodgkin’s lymphoma that has returned after prior treatment or hasn’t responded to it. Researchers are also studying combinations of brentuximab and nivolumab with chemotherapy as frontline treatment for early-stage disease, aiming to eliminate the need for radiation altogether in some patients.
Stem Cell Transplant for Relapsed Disease
If Hodgkin’s lymphoma comes back after initial treatment, the next step is usually a round of “salvage” chemotherapy to shrink the disease again, followed by an autologous stem cell transplant. In this procedure, your own stem cells are collected beforehand, high-dose chemotherapy is given to wipe out remaining cancer, and the stored stem cells are returned to rebuild your blood and immune system. For patients whose disease responds to salvage chemotherapy, this approach produces long-term disease control in 50% to 60% of cases. Even for disease that is partially resistant to chemotherapy, transplant still achieves progression-free survival rates of 40% to 45%.
If the disease returns after an autologous transplant, options include a second autologous transplant (which tends to work best if the relapse happened more than 12 months after the first one) or an allogeneic transplant using donor cells. Allogeneic transplant carries higher risks, including graft-versus-host disease, but it offers the potential for a donor immune system to recognize and attack remaining cancer cells. Two-year overall survival rates following donor transplant range from 52% to 66%, and newer approaches using partially matched family donors have shown encouraging results with three-year overall survival of 77% in some studies.
Treatment Differences for Children
Children and adolescents with Hodgkin’s lymphoma receive adapted treatment protocols designed to cure the cancer while minimizing harm to developing bodies. The core concern is avoiding drugs and doses that impair fertility or stunt growth. European pediatric protocols swap out procarbazine, a drug known to be highly toxic to reproductive function, in favor of alternatives like dacarbazine or etoposide. This substitution makes a dramatic difference: in one study, none of the young men treated with the modified regimen were infertile at follow-up, compared to the vast majority (19 out of 23) treated with the older combination who had no sperm production.
Radiation therapy alone is not recommended for children who haven’t finished growing, because the doses needed to control the tumor cause musculoskeletal problems. Instead, pediatric plans use combination chemotherapy with limited, low-dose radiation when needed, which helps preserve heart, lung, and reproductive function while reducing the risk of treatment-related leukemia later in life.
Fertility Preservation Before Treatment
Because several drugs used in Hodgkin’s treatment, particularly alkylating agents, can damage reproductive cells, fertility preservation should be discussed before treatment begins. For men and older adolescent boys, sperm banking is strongly recommended and should happen before the first dose of chemotherapy. Even a single treatment cycle can compromise sperm quality and DNA integrity. For those who can’t produce a sample through ejaculation, surgical sperm retrieval is an option.
For women, egg freezing (oocyte cryopreservation) or embryo freezing are both established options. Egg freezing is particularly suited to women without a partner or those who prefer not to create embryos. Both procedures require a stimulation cycle that typically takes about two weeks, so they need to be planned into the treatment timeline. Alkylating agents and radiation near the ovaries pose the greatest risk of premature ovarian insufficiency, and that risk increases with higher doses.
Long-Term Health Risks After Treatment
Surviving Hodgkin’s lymphoma is the expected outcome for most patients, which makes long-term side effects of treatment especially important to understand. Heart disease is the most significant concern. Patients treated with both radiation to the chest and a common class of chemotherapy drugs called anthracyclines face the highest risk. A large study of Hodgkin’s survivors found that anthracycline-based chemotherapy nearly tripled the rate of heart failure compared to regimens without it. When combined with higher radiation doses, the 25-year cumulative risk of heart failure reached roughly 33%, compared to about 4% for patients who received low-dose radiation without anthracyclines.
These risks don’t show up immediately. Heart problems typically develop 10 to 25 years after treatment, which is why long-term cardiac monitoring with regular imaging and screening is a standard part of survivorship care. The shift toward lower radiation doses and smaller treatment fields in modern protocols is specifically designed to reduce these late effects, though the full impact of these changes won’t be measurable for decades.
Survival Rates by Stage
Based on the most recent data from the National Cancer Institute’s SEER program (2016 to 2022), five-year relative survival rates for Hodgkin’s lymphoma are high across all stages. Stage I disease, confined to a single region, has a survival rate of 92.7%. Stage II, involving multiple regions on the same side of the diaphragm, actually has the highest rate at 95.4%, likely because these patients receive aggressive combined treatment. Stage III, where disease is on both sides of the diaphragm, drops to 87.7%, and stage IV, with diffuse involvement, comes in at 82.8%. These numbers reflect all patients diagnosed during that period, including older adults and those with other health conditions, so younger, otherwise healthy patients generally do better than these averages suggest.